Additionally, C1142, a rat/mouse chimeric monoclonal antibody, has been shown to neutralize CCL2 in a glioma mouse model, significantly reducing TAM numbers and improving survival [70]. This evidence concerns the gene CCL2 and central nervous system cancer.